Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (183)	6/18/1999 3:01:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 233

Thanks for the correction--I wonder if there is a way for RealPlayer to capture a streaming file as a big .wav, that might be something to look into--would be nice to have a copy. I would guess that the market is pricing MAGN on those odds being 10-15%, and not from the comments Zasloff made. And I suppose that is a safe and reasonable assumption--certainly no fund manager is going to plunge in until after the fact. I noticed Sciencemag.org is running a deal where you can subscribe to the website for 24hrs for just $10-- you may have noticed the Regeneron PR today, that paper would be one to grab, here is a snip from the abstract: This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. That one should be a pretty interesting read. I wonder if Magainin has any papers out there recently...I see from that last PR on Squalamine we have this: Squalamine is a small, synthetically produced molecule with a unique mechanism of action that blocks endothelial cell activation, migration and proliferation by multiple growth factors. This intracellular blockage of multiple growth factors contrasts to most other angiogenesis inhibitors currently under development that focus on a single growth factor or on a single stage of blood vessel recruitment. Preclinical studies have demonstrated that this multi-faceted approach may allow squalamine broad application across many cancer types, and the Company believes this approach will have a greater likelihood for success than angiogenesis blockade strategies that target only one specific receptor or adhesion molecule. Here is a link I may have posted before... cancertrials.nci.nih.gov Obviously Sugen and the MMP companies are ones to watch, although it's a little too late to whine about not owning SUGN;-)